Related Experiment Video
Updated: Dec 25, 2025

06:58
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
19.8K
Acute Cerebellitis and Atypical Posterior Reversible Encephalopathy Syndrome Associated with Methadone Intoxication.
Shafee Salloum1, Irma Reyes2, Elizabeth Ey3
1Department of Pediatric Hospital Medicine, Dayton Children's Hospital, Dayton, Ohio, United States.
Neuropediatrics
|March 22, 2020
Summary
A pediatric case revealed acute cerebellitis and atypical posterior reversible encephalopathy syndrome (PRES) in a 9-year-old boy after methadone exposure. Prompt medical intervention led to full recovery without lasting complications.
Area of Science:
- Pediatric Neurology
- Toxicology
- Neuroimaging
Background:
- Altered mental status and ataxia in children can indicate serious neurological conditions.
- Urine drug screens are crucial for identifying potential toxic exposures.
- Acute cerebellitis and posterior reversible encephalopathy syndrome (PRES) are distinct neurological emergencies.
Observation:
- A 9-year-old boy presented with vomiting, altered mental status, and ataxia.
- He required intubation due to rapid decline but improved and was extubated the next day.
- A urine drug screen was positive for methadone.
Findings:
- Initial brain imaging revealed acute cerebellitis.
- Following extubation, the patient developed hypertension and bradycardia, with subsequent imaging showing changes consistent with atypical PRES.
- Treatment with high-dose steroids and antihypertensives resolved the hypertension and neurological symptoms.
Implications:
- This case highlights the potential for methadone to trigger both acute cerebellitis and atypical PRES in pediatric patients.
- Early recognition and aggressive management of PRES symptoms are vital for favorable outcomes.
- This case underscores the importance of considering toxicological etiologies in pediatric neurological emergencies.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
737
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
737
Seizures: Classification
1.2K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Potassium Channel Activators
539
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
539

